lyra logo.jpg
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
September 03, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
lyra logo.jpg
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET | Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
lyra logo.jpg
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
August 04, 2020 08:00 ET | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
July 30, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 24, 2020 08:30 ET | Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Equillium_Square_Logo.png
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
July 13, 2020 03:30 ET | Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
lyra logo.jpg
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
July 07, 2020 08:30 ET | Lyra Therapeutics
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
June 25, 2020 08:00 ET | Lyra Therapeutics
WATERTOWN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
lyra logo.jpg
Lyra Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 28, 2020 16:05 ET | Lyra Therapeutics
WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...